Impact of Travel Time on Health Care Costs and Resource Use by Phase of Care for Older Patients With Cancer Although patients with NSCLC treated with ≥ 10 mg of prednisone at the time of immunotherapy ...
Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems? The following represents disclosure information provided by authors of this manuscript. All relationships ...
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma Eligible survivors of ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy A significant overall survival (OS) benefit of ...
Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer In a prospective cohort study, 111 patients who had rectal cancer treated by neoadjuvant therapy ...
Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node ...
At a cancer center in Alberta, Canada, consecutive patients with cancer (lung or GI; N = 1,473) were assessed at presentation for weight loss history, lumbar skeletal muscle index, and mean muscle ...
Patients with head and neck squamous cell carcinoma (HNSCC) are at elevated risk of second primary malignancies (SPM), most commonly of the head and neck (HN), lung, and esophagus. Our objectives were ...
Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer Clinically annotated, microarray data from 784 ...
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720 Most ...
View the current volume of the ASCO Educational Book ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results